Avid Bioservices Inc (CDMO)

[hutschi]

Antibody targeting of phosphatidylserine for detection and immunotherapy of cancer

Abstract
Metrics
Get Permission
Authors Zohar DN, Shoenfeld Y

Received 27 March 2018

Accepted for publication 7 April 2018

Published 22 June 2018 Volume 2018:7 Pages 51—53

DOI https://doi.org/10.2147/ITT.S169383

Checked for plagiarism Yes

Editor who approved publication: Professor Michael Shurin

Daniela Noa Zohar, Yehuda Shoenfeld

Zabludowitz Centre for Autoimmune Diseases, Sheba Medical Centre, Tel-Hashomer, Israel

Belzile et al introduce a novel therapeutic approach for cancer by antibody targeting of phosphatidylserine (PS).1 As is well known, antiphospholipid autoantibodies are associated with hypercoagulability disorders, particularly antiphospholipid syndrome (APS).2 While the hallmark autoantibodies of APS are anti-beta2 glycoprotein and anticardiolipin, over 30 other non-classic autoantibodies were reported in correlation with APS. Particular attention was dedicated to antiphosphatidylserine (aPS) – a remarkable autoantibody that was detected in 68–86% of APS patients.2 aPS is associated with thrombosis, thrombocytopenia and hemolytic anemia.2 Previously, we have described the pathogenicity of aPS on experimental mice models by induction of APS, both through passive transfer of purified human IgG aPS antibodies3 and active immunization, whereas immunized mice with IgG aPS produced high titers of mouse aPS. The results demonstrated a clinical picture of APS by prolonged activated partial thromboplastin time, thrombocytopenia and increased rates of fetal resorptions.4


https://www.dovepress.com/aantibody-targeting-of-phosphatidylserine-for-the-detection-and-i-peer-reviewed-article-ITT


Download Article!!!